Sign in
IBRX Stock Price, Chart, Stats & News
ImmunityBio, Inc.
Save
8.10B
Market cap
–
Current P/E
–
Forward P/E
IBRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 92.44% |
Operating margin | -226.00% |
Pretax margin | -310.37% |
Net margin | -310.18% |
Effective tax rate | 0.04% |
ROA | -70.01% |
ROE | 64.30% |
D/E | -1.76x |
Interest coverage ratio | -2.28x |
IBRX valuation
P/E | – |
P/S | 66.97x |
P/B | -14.62x |
P/CF | -23.95x |
P/FCF | -24.63x |
P/OCF | -23.95x |
PEG | -4.16x |
EV multiple | -30.41x |
About
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms.
Similar securities
Based on sector and market capitalization
Report issue